Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

ConditionSSTR Positive Tumors

Trial statusRecruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences

About this trial

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with suspected or clearly diagnosed SSTR positive tumors

signed written consent.

Willing and able to cooperate with all projects in this study.

Disqualifiers

pregnancy;

breastfeeding;

any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Trial design

Design model

Single group

Treatments tested in this trial

Al18F-octreotide
Drug
Al18F-octreotide I was injected into the patients before the PET/CT scans

Treatment groups

400 Participants

are divided into 1 treatment group

Group A: Al18F-octreotide PET/CTExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Diagnostic value

Sensitivity and Specificity of Al18F-octreotide PET/CT for SSTR positive tumors

Time frame

through study completion, an average of 1 year]

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Lead sponsor

Source ClinicalTrials.gov

Apply now